Omid Farokhzad is the CEO of Seer, Inc., a company he founded in 2017 to revolutionize the field of proteomics. A serial entrepreneur and former professor at Harvard Medical School, Farokhzad has a distinguished career marked by significant contributions to nanomedicine and biotechnology.
Who is the CEO of Seer?
Omid Farokhzad is a distinguished figure in the biotechnology sector, known for his pioneering work in nanomedicine and proteomics. Farokhzad's career includes founding several successful biotech companies, such as BIND Therapeutics, Selecta Biosciences, and Tarveda Therapeutics. Before his entrepreneurial ventures, he was a professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. His extensive contributions to the field are underscored by over 200 issued or pending patents and numerous prestigious awards.
Currently, as the CEO of Seer, Inc., Farokhzad is leading efforts to transform protein research, positioning the company at the forefront of proteomics innovation.
Work History
Omid Farokhzad's extensive work history showcases his leadership and expertise across various prestigious institutions and companies. Here is a detailed list of his professional roles:
- Seer - Chair, CEO and Founder (2018 - Present)
- PrognomiQ Inc - Chair and Founder (2020 - Present)
- Senti Biosciences - Director (2022 - Present)
- Harvard Medical School - Professor of Anesthesiology (2004 - 2020); Senior Lecturer (2020 - Present)
- Dynamics Special Purpose Corp. - Executive Chair and Founder (2021 - 2022)
- Selecta Biosciences - Director, Chairman (2008 - 2019) and Founder (2008 - 2022)
- Tarveda Therapeutics (Formerly Blend Therapeutics) - Director (2011 - 2019) and Founder (2011 - 2021)
- Brigham and Women's Hospital - Director, Center for Nanomedicine (2016 - 2020), Lab of Nanomedicine (2004 - 2020)
- BIND Therapeutics - Director (2006 - 2014) and Founder (2006 - 2015)
Education History
Omid Farokhzad's educational journey is marked by a series of prestigious institutions and specialized training. He began his academic career at Boston University School of Medicine, where he earned both an M.D. and an M.A. Following this, he pursued an M.B.A. at MIT Sloan School of Management, further broadening his expertise. Farokhzad then completed a post-doctoral fellowship in Nanomedicine and Biomaterials at the Harvard-MIT Division of Health Sciences and Technology, a collaborative program between Harvard and the Massachusetts Institute of Technology. Additionally, he undertook a residency in Anesthesiology and a fellowship in Pain Medicine at Harvard Medical School and Brigham and Women's Hospital, solidifying his foundation in both clinical and research domains.
When did Omid Farokhzad join Seer?
Omid Farokhzad founded Seer, Inc. on March 1, 2018, and has been serving as its CEO since its inception. As of now, he has been with Seer for over five years, leading the company in its mission to revolutionize the field of proteomics.
Farokhzad's extensive background in biotechnology and his leadership at Seer underscore his commitment to advancing protein research and innovation.